Published online Jan 27, 2026. doi: 10.4240/wjgs.v18.i1.114262
Revised: October 24, 2025
Accepted: November 21, 2025
Published online: January 27, 2026
Processing time: 123 Days and 3.8 Hours
Hepatocellular carcinoma (HCC) commonly arises in cirrhotic livers. Laparoscopic hepatectomy (LH) has shown promising outcomes, but its safety in mode
To compare short-term and long-term outcomes of LH and OH in patients with HCC LDGS grade B or C.
The 97 patients with HCC and LDGS grade B or C who underwent hepatectomy (26 LH; 71 OH) between 2010 and 2022 at Tokyo Women’s Medical University Hospital were retrospectively analyzed. Propensity score matching (1:1) was applied. Baseline biochemical and tumor characteristics were compared. Short-term and long-term outcomes were assessed.
Before matching patients who underwent LH had smaller tumors (2.7 cm vs 4.5 cm, P = 0.004) and lower surgical difficulty scores (P < 0.001). After matching LH was associated with lower intraoperative blood loss (242 mL vs 941 mL; P = 0.049), reduced postoperative ascites (0% vs 21.2%; P = 0.035), and shorter hospital stay with no conversion to OH. The 5-year overall survival rate was significantly higher in the LH group (91% vs 36%; P = 0.021) while recurrence-free survival was comparable.
LDGS provides a comprehensive assessment of surgical candidates with moderate cirrhosis. In patients with HCC and grade B or C liver damage, LH appears to have better long-term outcomes than OH due to reduced morbidity and preservation of liver function.
Core Tip: Laparoscopic hepatectomy (LH) is a feasible and safe procedure for patients with hepatocellular carcinoma and moderate cirrhosis, particularly Liver Damage Grading System grade B or C. In this single-center retrospective study with propensity score matching, LH significantly reduced intraoperative blood loss and postoperative ascites, shortened hospital stay, and improved 5-year overall survival compared with open hepatectomy. The Liver Damage Grading System provides a practical tool for selecting surgical candidates. These findings support LH as a preferred approach in patients with hepatocellular carcinoma and grade B liver damage, optimizing long-term outcomes while preserving liver function.
